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Abstract
Numerical and functional defects of invariant natural killer T cells (iNKT) have been documented in human and mouse
cancers, resulting in a defect in IFN production in several malignancies. iNKT cells recognize glycolipids presented on CD1d
molecules by dendritic and related cells, leading to their activation and thereby regulating immune reactions. Activated
iNKT cells cytokine secretion and cytotoxicity can inhibit existing and spontaneous tumor growth, progression, and
metastasis. We have identified functional iNKT cell defects in the murine TRAMP prostate cancer model. We found that iNKT
cells show the ability to migrate into TRAMP prostate tumors. This infiltration was mediated through CCL2: CCR5
chemokine: receptor interaction. Prostate tumor cells expressing CD1d partially activated iNKT cells, as appreciated by up-
regulation of CD25, PD-1 and the IL-12R. However, despite inducing up-regulation of these activation markers and, hence,
delivering positive signals, prostate tumor cells inhibited the IL-12-induced STAT4 phosphorylation in a cell-cell contact
dependent but CD1d-independent manner. Consequently, tumor cells did not induce secretion of IFNc by iNKT cells.
Blocking the inhibitory Ly49 receptor on iNKT cells in the presence of a-GalCer restored their IFNc production in vivo and in
vitro. However, Ly49 blockade alone was not sufficient. Importantly, this defect could be also be reversed into vigorous
secretion of IFNc by the addition of both IL-12 and the exogenous CD1d ligand alpha-galactosylceramide, but not by IL-12
alone, both in vivo and in vitro. These data underscore the potential to optimize iNKT-based therapeutic approaches.
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Introduction
Invariant natural killer T (iNKT) cells are a subset of
lymphocytes with an important role in regulating immune
responses, including immune surveillance. iNKT cells recognize
lipid antigens presented by the monomorphic MHC-like molecule
CD1d. They were initially identified based on their restricted T
cell receptor repertoire used. The hallmark of iNKT cells and basis
of their regulatory function is the rapid secretion of multiple
cytokines upon TCR triggering accompanied with an increased
cytotoxic capacity [1]. The cytokines secreted by iNKT cells
include both regulatory cytokines (e.g. IL-4, IL-10) as well as pro-
inflammatory cytokines such as IL-2, and IFNc, reflecting their
capacity to suppress or stimulate immune responses [2]. Although
a panel of exogenous CD1d ligands including the prototypic high-
affinity lipid alpha-galactosylceramide (a-GalCer) have been
reported to date, the identity of physiological endogenous ligands
that mediate CD1d-dependent iNKT cell activation remains
ambiguous [3]. While the function of iNKT cells as positive or
negative regulators of immune responses has been widely
acknowledged [2,4], the exact mechanisms polarizing their
effector functions are elusive.
Studies in multiple human cancers and animal models revealed
numerical and functional defects in iNKT cells. Decreased
numbers of circulating iNKT cells were accompanied by a
decrease in IFNc production by iNKT cells in advanced prostate
cancer and other cancers, concurrent with increased IL-4
production upon re-stimulation in vitro [5–9]. The activation of
iNKT cells with a-GalCer promotes tumor rejection and protected
from the development of metastasis in multiple mouse models and
injection of a-GalCer-pulsed DC further improves this effect
[10–12]. However, previous studies also showed that some CD1d-
restricted non-invariant NKT cells can suppress anti-tumor
responses [13].
The contribution of iNKT cells in immune surveillance is at
least partly based on their capacity to mature dendritic cells (DC)
and subsequently activate natural killer (NK) cells, the latter of
which become potent cytotoxic cells. Upon recognition of
CD1d:lipid complexes and the co-stimulatory molecules CD80/
86 on the surface of DCs, iNKT cells up-regulate the IL-12R and
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cells then induce maturation and production of IL-12 in DCs. This
IL-12 release potently increases IFNc production by iNKT cells
[14,15].
IL-12 was initially described as a master regulator of Th1
responses [16], and, like a-GalCer, drives the anti-metastatic
activity of T cells including iNKT cells [10]. Several pre-clinical
and clinical trials using IL-12 have been conducted to improve
immunotherapy for cancers [17]. Whether defects of iNKT cells
are mediated by intrinsic causes or by an impaired stimulatory
capacity of DC present in the tumor microenvironment is not
known. Moreover, it is not known whether DC and iNKT cells
undergo a sustained functional inhibition in tumors or whether
their functions can be restored by adjuvants like IL-12 in vivo.
In this study we sought to establish a murine prostate cancer
model to study iNKT cell defects and determine if their functions
are inhibited by tumor cells. We found functional iNKT cell
defects in the prostate cancer model TRAMP (transgenic
adenomacarcinoma of the mouse prostate) resembling those
functional iNKT cell defects seen in human malignancies. iNKT
cells were attracted by tumor cells to migrate into prostate tumors
mediated through the CCL2-CCR5 axis. Both primary prostate
tumors as well as mouse and human CaP cell lines express high
levels of CD1d, permitting direct interaction with iNKT cells.
We found that prostate tumor cells induced the production of
Th2 cytokines by iNKT cells. These tumor cells and murine
prostate tumors specifically induced the up-regulation of activation
markers IL-12R, CD25 and PD-1 on iNKT cells. Parallel,
TRAMP-C2 cells cell-contact dependently blocked IL-12 mediat-
ed STAT4 phosphorylation in iNKT cells. This aberrant iNKT
cell activation was correctable by simultaneous addition of the
exogenous CD1d ligand a-GalCer and IL-12, and allowed iNKT
cells to produce IFNc in response to tumor cells. Blocking Ly49
inhibitory NK receptor also rescued the IFNc production of iNKT
cells stimulated by TRAMP-C2 cells in the presence of a-GalCer.
Conceivably, the restoration of the iNKT cell functions (e.g. IFNc
production) by addition of IL-12 or Ly49 neutralization provides a
tempting possibility for overcoming iNKT cell defects in
malignancy.
Materials and Methods
Mice
C57Bl/6J were purchased from Jackson Laboratories (Bar
Harbor, MA). TRAMP mice were described previously [18]. For
experiments, 6- to 8-wk-old and 15- to 35-wk-old C57BL/6J mice
and heterozygous TRAMP mice at 15 to 35 weeks of age were
used. All mice were housed in the specific pathogen-free animal
facility at Beth Israel Deaconess Medical Center. Animal
experiments were approved by the Institutional Animal Care
and Use Committee (protocol 075-2009).
Reagents
PBS57-loaded and empty CD1d monomers and tetramers were
provided by the NIH tetramer facility (Emory Vaccine Center,
Atlanta, GA). The following monoclonal antibodies (mAbs) and
secondary reagents were used: mouse CD1d PE (1B1), human
CD1d PE (42.1), CD3 FITC, CD4-APC-Cy7, NK1.1 PE, purified
anti-CD16/32, CD69 PE-Cy7, CD212 biotin, purified anti-
CD16/32, streptavidin-APC-Cy7, were from BD Biosciences.
abTCR AlexaFluor700, PD-1 PE, CD25 PerCP-Cy5.5, I-A/I-E
Pacific Blue, purified anti-Ly49C/F/H/I were purchased from
eBioscience, anti-PD-L1 and Ly49C/F/I/H were purchased from
Biolegend and pSTAT4 (Ser721) was purchased from Santa Cruz.
Cell culture of TRAMP-C2
Cells were cultured in RPMI-1640 supplemented with Penicillin
and Streptomycin (Mediatech, Manassas, VA) and 5% FCS
(Hyclone, Logan, UT). The cell lines TRAMP-C2, DU145, PC3,
LNCaP and Hela were maintained in cell culture medium and
split using trypsin digestion when 80% confluence was reached.
The prostate epithelia PrEC were maintained in PrEGM Bullet
Kit medium (Cambrex, Charles City, IA) and split every 2–4 days
by brief trypsination.
Bone-marrow derived DC (BM-DC)
BM-DC were generated from wildtype (WT) mouse BM in the
presence of GM-CSF as described by Inaba et al. [19] with
modifications. Briefly, BM cells were cultured in complete medium
supplemented with 5% culture supernatants of GMCSF-produc-
ing B16F10 (kind gift of Dr. Dranoff, Dana-Farber Cancer
Institute, Boston, MA), replaced every other day until day 6 of
culture.
Spleen and liver preparations
Single cell suspensions from spleens were prepared by standard
techniques. Liver mononuclear cells (MNC) were isolated as
previously described [20]without prior Collagenase digestion. Briefly,
livers were perfused with PBS, minced and MNC were enriched by
centrifugation in a two-step (40%/ 60% (w/v) Percoll) gradient.
Enriched populations typically contained 20–30% iNKT cells.
Tumor-infiltrating lymphocytes (TIL)
Primary tumors of TRAMP mice were minced and digested for
1h ra t3 7 uC in complete medium with Collagenase (Stemcell
Technologies, Vancouver, BC, Canada), Hyaluronidase (10 U/
mL) and DNase I (10 mg/ml, Sigma-Aldrich, St.Louis, MO). TIL
were further enriched by Percoll centrifugation as described [20].
In vivo stimulation of iNKT cells
TRAMP or C57BL/6 mice were injected i.p. with 2 mg a-
GalCer or vehicle (Tween-20). Blood was collected from sacrificed
mice by heart puncture at indicated timepoints and coagulated at
RT. Sera were collected after centrifugation at 4006g for 10 min
and stored at 280uC until further analysis.
In vivo stimulation of iNKT cells
C57BL/6 mice were injected with 5610
6 exponentially grown
TRAMP-C2 cells in PBS s.c. in both flanks. Two weeks later mice
were i.p. injected with combinations of 150 mg Brefeldin A (Sigma-
Aldrich), 1 mg a-GalCer, and 500 ng recombinant mouse IL-12
(RndSystems). 5 hours later livers and spleen were taken and
immediately stored in ice-cold PBS.
Ex vivo stimulation of iNKT cells
iNKT cells from livers were stimulated in the presence of either
BM-DC or TRAMP-C2 cells (pulsed with a-GalCer or vehicle).
BM-DC or TRAMP-C2 cells were pulsed with a-GalCer (200 ng/
ml) for 3 hrs at 37uC and washed three times with medium.
ELISA
Cytokine-specific ELISA assays (eBioscience, San Diego, CA)
were performed following the manufacturers instructions. Sera
were diluted 1:10 in PBS/1% BSA.
Immunofluorescence and microscopy
TRAMP-C2 cells were cultured on cover slips overnight and
fixed using methanol/ aceton. Nonspecific binding was reduced
iNKT Cells and Prostate Cancer
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DAPI and PE-conjugated anti-CD1d mAbs (BD Biosciences, San
Jose, CA) at 4uC. Imaging was performed using a Axiovert
microscope (Zeiss, Jena, Germany).
Flow cytometry
Subsequently to blocking with anti-CD16/32 mAbs cells were
stained with indicated mAbs and CD1d tetramers. Flow cytometry
was performed on a FACS LSR II (BD Biosciences, San Jose, CA).
Flow cytometry data were analyzed using FlowJo 8 (Treestar,
Ashland, OR).
Intracellular cytokine stainings
Spleen cells and liver MNC were blocked with anti-CD16/32
mAbs, washed and stained using mAbs against abTCR, NK1.1.
After washing cells were fixed for 15 mins. with 2% Paraformal-
dehyde in PBS. Cells were then permeabilized with 0.5% Saponin,
1% BSA in PBS for 15 mins. All further steps were carried out in
permeabilization buffer. Cells were washed and stained with mAbs
against IFNc, IL-4 or rat IgG1 isotype controls before two final
washes with permeabilization buffer and PBS, respectively.
Western Blot
Cell lysates were separated by SDS-PAGE (12.5%) under
reducing or non-reducing conditions as shown and subsequently
transferred to PVDF membranes,which were blocked with 5%milk
in TBS-T (TBS, pH 8.0, 0.1% Tween 20). The membranes were
then incubated with rat anti-mouse CD1d IgM (3C11) antibody
(1:1000 dilution) or rat anti-mouse CD1d IgG HB323 (1 mg/ml;
kind gift of A. Bendelac) overnight at 4uC. Subsequently, the
membranes were washed and incubated with a secondary HRP
conjugated goat anti-rat IgM or anti-IgG antibody at 1:2000
(Pierce). Bands were visualized using enhanced chemiluminescence
(ECL, Amersham Biosciences).
Migration assay
Migration assays were performed in 24-well plates with 5 mm
transwell inserts (Corning Costar). Liver MNC were pre-incubated
with anti-CCR5 or isotype control mAbs (each 50 mg/ml) 15 min
before adding to transwell inserts (2.5610
4/well) and allowed for
3 hrs to migrate against TRAMP-C2 cells. Migrated non-adherent
cells were stained with PBS57-loaded CD1d tetramers and mAbs
against CD3, NK1.1, abTCR. 1610
4 splenocytes loaded with
A
B
Figure 1. Tumor-bearing TRAMP mice exhibit defective cytokine production in vivo by iNKT cells and DC, albeit harboring normal
iNKT cell frequencies. A. Cell suspensions of spleens and livers of WT and TRAMP mice were stained with mAbs against CD3, NK1.1 and PBS-57-
loaded CD1d tetramers and analyzed by FACS, identifying comparable numbers of iNKT cells. (n=5). B. TRAMP mice or age-matched C57Bl/6 mice
were injected with a-GalCer. Mice were sacrificed 90 min (IL-4, IL-10) and 300 min later (IFNc, IL-12 p70) and cytokines determined by ELISA. (*, p,0.05,
***, p,0.001, n.d, not detectable, n=3).
doi:10.1371/journal.pone.0011311.g001
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analyzed by FACS. Numbers of migrated iNKT cells were
calculated using the formula:
%Indo{=%Indo{1zcells x 104
100  %CD3zNK:1zCD1d
{tetramerzabTCRz:
Statistical analyses
Results are expressed as mean 6 SD. For statistical analyses the
One-way-ANOVA with Newman-Keuls post-test was used.
Values of p,0.05 were considered as significant. Data were
analyzed using Prism 5 (GraphPad, La Jolla, CA).
Results
Impaired iNKT cell cytokine responses in tumor-bearing
mice
We first sought to analyze whether prostate cancer-bearing mice
exhibit numerical and functional iNKT cell defects comparable to
those reported in cancer patients [6–9].
We quantitated iNKT cell frequencies from spleens and livers of
TRAMP and WT control mice by flow cytometry (Fig. 1A). iNKT
cells can be identified by their reactivity to CD1d tetramers loaded
withthe a-GalCer analogue PBS57 [21]. Consistent witha previous
report [22], both groups of mice showed age-dependent increases in
liver iNKT cell frequencies. In addition, we observed age- but not
strain-dependent increases in absolute iNKT cell numbers in livers
and spleens (data not shown). In contrast to humans where relative
large cohorts of cancer patients and healthy individuals have been
studied, in mice we found that tumor-bearing mice exhibited iNKT
cell frequencies comparable to age-matched WT mice (Fig. 1A).
To assess iNKT cell function, WT and TRAMP mice were
injected with the exogenous CD1d ligand a-GalCer to activate iNKT
cells systemically. We then measured IFNc as a Th1 cytokine, the
Th2 cytokines IL-4 and IL-10, all of which are produced by iNKT
cells. Additionally, we measured IL-12, a product of DC. Upon
CD1d:TCR interaction in WT mice DC are stimulated by iNKT
cells to produce IL-12 which in turn enhances the IFNcproduction of
iNKT cells. The injection of a - G a l C e rt oW Tm i c er e s u l t e di n
enhanced serum levels of IL-4 and IL-10 at 90 minutes after
activation. At 5 hrs after injection we detected high levels of IFNc
and IL-12 in the serum (Fig. 1B). TRAMP mice, however, showed
significantly reduced levels of IL-4, IL-10 and IFNc upon a-GalCer
administration. Concomitantly to the reduced IFNc levels in
TRAMP mice, IL-12 was undetectable upon a-GalCer administra-
tion. Collectively, these results show pronounced defects in the
cytokine production of both DC and iNKT cells in tumor-bearing
mice. This defect involved Th1 as well as Th2 cytokines.
CCR5-mediated iNKT cell migration into murine prostate
tumors
We next questioned whether iNKT cells infiltrate the primary
prostate tumors of TRAMP mice. TRAMP tumors were
enzymatically dissociated and TILs were enriched by Percoll
density gradient centrifugation. To identify iNKT cells, we gated
on CD45
+CD3
+CD1d tetramer
+ cells. As Fig. 2A shows, we
identified a distinct population of iNKT cells in the lymphocyte
infiltrate of TRAMP tumors (mean of 3.65%) comparable to
frequencies in the spleens of both groups (Fig. 1A). Based on results
shown in Fig. 1 spleens of both groups harbored similar
frequencies of iNKT cells. In contrast, we found a larger
population of iNKT cells among the lymphocytes in prostate
tumors compared to spleens, suggesting iNKT cells are actively
recruited into these tumors.
The presence of iNKT cells in the tumor infiltrate prompted us
to ask whether the mouse prostate tumor cells attract iNKT cells.
Both murine and human iNKT cells express a chemokine receptor
repertoire indicative of preferential homing into peripheral non-
lymphoid tissues and to sites of inflammation [23,24]. Human
prostate tumors as well as well as primary prostate epithelial cells
(PrEC) are known to secrete the chemokine CCL2 (MCP-1)
[25,26]. The expression of CCL2 in mouse tumors and TRAMP
mice in particular is not known. CCL2 binds the two chemokine
receptors CCR5 and CCR2 which is expressed on iNKT cells
[24,27]. CCL2 has recently been shown to mediate iNKT cell
migration into human neuroblastoma [28].
We first tested whether mouse prostate tumors and the derived
cell line TRAMP-C2 secrete CCL2. TRAMP-C2 cells produce
CCL2 as appreciated by intracellular staining for CCL2 (Fig. 2B,
right) and secrete CCL2 (Fig. 2B. bar graph). Importantly, primary
tumors of TRAMP mice were found to produce CCL2 as shown
by flow cytometry (Fig. 2B, right histogram).
We hypothesized that the relative abundance of iNKT cells
among the TIL compared to spleen would be reflected in
preferential chemokine receptor expression. In contrast to spleens
of both groups the majority of iNKT cells in the prostate tumors
were found to express high levels CCR5 on their surface (Fig. 2C).
In contrast to CCR5 we did not observe a higher expression of
CCR2 on TIL-iNKT cells (data not shown), excluding a critical
role of CCR2 in the migration of iNKT cells into tumors.
Employing a transwell migration system, we next asked whether
attraction of iNKT cells is mediated by CCR5 (Fig. 2D). We found
that TRAMP-C2 cells producing CCL2 stimulated iNKT cell
migration through transwell membranes as compared to the
medium control. The pre-incubation of liver MNC with blocking
anti-CCR5 antibodies reduced the migration of iNKT cells to
background levels. Collectively, these data indicate the
CCL2:CCR5-mediated iNKT cell attraction by prostate tumor
cells and strongly suggest that CCR5 and CCL2 play critical roles
in iNKT cell migration into prostate tumors.
Murine prostate tumors express functional CD1d
CD1d is expressed primarily by hematopoetic cells [29,30], but
low levels of expression also have been found on hepatocytes and
intestinal epithelial cells [31,32]. With the exception of tumors
arising from naturally CD1d
+ tissues and cell types such as
lymphoid and myeloid neoplasm [33,34], the expression pattern of
CD1d on malignant cells is largely unknown. The relative
abundance of iNKT cells in the TRAMP tumor led us to
Figure 2. iNKT cells migrate into murine prostate tumors. A. WT splenocytes (row 1), TRAMP splenocytes (row 2), and TRAMP prostate-TIL
(row 3) were stained with indicated mAbs. CD45
+MHC class II
2 cells (left) were gated and analyzed for the expression of CD69. B. Left: CCL2 content
in culture medium of TRAMP-C2 cells cultured overnight as measured by ELISA. Histograms: CCL2 expression in TRAMP-C2 cells (left) and primary
TRAMP tumor cells (right), (dashed lines: isotype controls). C. CCR5 expression on gated iNKT cells shown in A (dashed lines: isotype controls). D. Liver
IHL were incubated with medium, anti-CCR5 or isotype controls and allowed to migrate towards TRAMP-C2 or medium. Migrated iNKT cells were
quantified by flow cytometry. Data shown in A–C, and D are representative of 3 and 2 experiments, respectively.
doi:10.1371/journal.pone.0011311.g002
iNKT Cells and Prostate Cancer
PLoS ONE | www.plosone.org 5 June 2010 | Volume 5 | Issue 6 | e11311iNKT Cells and Prostate Cancer
PLoS ONE | www.plosone.org 6 June 2010 | Volume 5 | Issue 6 | e11311investigate whether murine prostate cancer cells express CD1d
and can activate iNKT cells by CD1d-dependent mechanism.
TRAMP-C2 cells stained with CD1d-specific mAbs and
analyzed by flow cytometry showed clear CD1d surface expression
that was higher than expression on splenocytes used as positive
controls. The CD1d expression was further confirmed by Western
blot using the rat-anti mouse CD1d IgM clone 3C11 (a similar
staining was obtained using the rat anti-mouse CD1d IgG clone
HB323, data not shown) and fluorescence microscopy (Fig. 3A).
To assess CD1d expression by primary prostate tumor cells from
TRAMP mice were isolated by enzymatic dissociation and stained
with mAbs against lineage-markers CD45, Gr-1, MHC-II, and
CD1d. Gating on lineage marker-negative tumor cells revealed a
clear signal of CD1d expression (Fig. 3B).
To determine whether the CD1d expression on these T-antigen
induced prostate tumors would translate into human prostate
cancers, we tested a panel of human CaP cell lines. DU-145, PC3,
and LNCaP expressed CD1d on their surface compared to the
CD1d transfected cell line Hela (Fig. 3C). Significantly, also the
untransformed human prostate epithelial cells (PrEC) expressed
CD1d molecules. These results indicate that CD1d expression is
intrinsic to prostate epithelium and suggest that prostate tumors
can directly interact with iNKT cells.
Whether the CD1d expression on prostate tumor cells is
functional and can activate iNKT cells was tested using the iNKT
cell hybridoma DN32. We used TRAMP-C2 cells pulsed with the
exogenous CD1d ligand a-GalCer to stimulate DN32 cells, which
secrete only IL-2 upon TCR ligation [35]. In the absence of a-
GalCer, TRAMP-C2 cells were not able to stimulate the DN32
cells, as seen by lack of IL-2 production (Fig. 3D, top bar). In
contrast, DN32 responded vigorously to TRAMP-C2 cells in the
presence of a-GalCer, which was specifically reduced by anti-
CD1d mAbs.
Murine prostate tumors defectively activate iNKT cells
Having demonstrated the functionality of CD1d expression on
TRAMP-C2 cells (Fig. 3D), we next asked which cytokine profile
these tumor cells stimulate in primary iNKT cells. We exposed
freshly isolated murine hepatic iNKT cells from healthy mice to
TRAMP-C2 cells alone, and examined their cytokine production.
BM-DC were used as positive controls for iNKT cell stimulation.
As expected, iNKT cells produced high levels of both IL-4 and
IFNc in response to a-GalCer-pulsed DC, and IFNc production
was dependent on a-GalCer (Fig. 4A). However, iNKT cells
produced IL-4, but no IFNc, in response to TRAMP-C2. Pulsing
TRAMP-C2 cells with a-GalCer increased the IL-4 expression by
iNKT cells to a magnitude comparable of BM-DC (Fig. 4A, bar 3).
This regimen, however, induced only marginal amounts of IFNc
from NKT cells.
These data prompted us to examine the of typical activation
markers on iNKT cells upon stimulation with TRAMP-C2 cells.
IL-12 mediates its effects by binding to a heterodimeric receptor
comprised of two chains, of which the b1 chain is up-regulated
during activation of conventional T cells and expressed at low
levels on resting iNKT cells [36,37]. As shown in Fig. 4B, we
detected up-regulation of the IL-12Rb1 chain 36 hrs after contact
with TRAMP-C2 cells. Importantly, exposure to TRAMP-C2
cells without addition of a-GalCer was sufficient to achieve this
effect. In contrast, DC, confirmed as superior iNKT cell
stimulators (Fig. 4A), led only to a small increase in IL-12Rb1
expression on iNKT cells, whether or not in the presence of a-
GalCer (Fig. 4B).
Concomitantly, exposure to TRAMP-C2 cells (with and without
a-GalCer) increased expression of PD-1 on iNKT cells, whereas
BM-DC failed to induce this effect. iNKT cells express PD-1 upon
activation in vivo and can subsequently enter an anergic-like state
[38,39]. How PD-1 is regulated in vitro is unclear. Despite this clear
PD-1 upregulation, the IFNc expression of iNKT cells stimulated
with TRAMP-C2 cells was independent of interactions between
PD-1 and PD-L1, which can be explained by the lack of PD-L1
expression by TRAMP-C2 cells (Figure S1). As expected, based on
responses to IL-12, IL-12Rb1 was induced by a-GalCer pulsed
TRAMP-C2 cells (Fig. 4B). Interestingly, IL-12Rb1 was also
induced by TRAMP-C2 cells without a-GalCer (Fig. 4B).
Phosphorylation of STAT4 transcription factor in position
Ser721 and Tyr693 is critical for IL-12R mediated signaling [40].
We tested whether preincubation of iNKT cells with TRAMP-C2
cells would block subsequent IL-12-mediated IL-12R signaling.
Liver MNC of healthy WT mice were co-cultured with TRAMP-
C2 cells and subsequently stimulated with IL-12 before STAT4
phosphorylation was examined by flow cytometry (Fig. 4C). IL-12
stimulation for 30 mins. resulted in the phosphorylation of STAT4
compared to un-stimulated control (MFI values 281 vs. 427). The
pre-incubation with TRAMP-C2 cells blocked the STAT4
phosphorylation in iNKT cells (MFI 264). Furthermore, we tested
whether this phosphorylation blockade was mediated by expres-
sion of CD1d on tumor cells or soluble mediators and co-cultured
iNKT cells with TRAMP-C2 in the presence of CD1d blocking
antibodies or separated by transwell membranes. Blocking of
CD1d on TRAMP-C2 cells using saturating amounts before and
during culture did not restore subsequent IL-12 mediated STAT4
phosphorylation (MFI 268). However, membrane separation
between TRAMP-C2 and iNKT cells was sufficient to restore
IL-12R signaling in iNKT cells, leading us to conclude that
TRAMP-C2 cells CD1d-independently but cell-cell contact
dependently block IL-12R signaling in iNKT cells.
IL-12 and a-GalCer restore iNKT cell activation in
response to prostate tumor cells
In light of the IL-12R up-regulation observed in vitro (Fig. 4B),
we further characterized TIL-iNKT cells present in TRAMP
tumors. Although we did not see any up-regulation of PD-1 or
CD25 molecules on iNKT cells in TRAMP mice (data not shown),
we consistently found strong up-regulation of IL-12Rb1 on TIL-
iNKT cells in tumor, but not from spleens, in both groups (Fig. 5A).
The up-regulation of IL-12Rb1 was specific for iNKT cells, as it
was not detectable on conventional T cells (Fig. 5A), further
corroborating our hypothesis of CD1d-mediated iNKT cell partial
Figure 3. Prostate tumors, primary prostate epithelium, and prostate tumor cell lines express CD1d. A. Row 1: CD1d expression of
TRAMP-C2 cells (bold line) and WT splenocytes (thin line)(dashed line: isotype control), as analyzed by FACS. Top right: CD1d protein expression of
TRAMP-C2 cells as determined by Western Blot using rat-anti-mouse CD1d mAb (3C11). Row 2: Fluorescence micrographs show TRAMP-C2 cells
stained against mouse CD1d (left) and DAPI (center). B. CD1d expression of primary mouse prostate tumors. Contour plot: Gating of Gr-1
2, MHC-
classII
2 cells from CD45
2 tumor cells. Histogram: CD1d expression on gated tumor cells stained against mouse CD1d (solid) or isotype control
(dashed line). C. CD1d expression in human CaP cell lines and primary prostate epithelium stained with human CD1d or isotype controls (dashed
lines). D. TRAMP-C2 cells express functional CD1d. TRAMP-C2 were pulsed with a-GalCer or vehicle, washed, loaded with anti-CD1d or isotype
control mAbs and incubated with DN32 iNKT hybridoma cells overnight. IL-2 in cell culture supernatants was measured by ELISA. Data shown are
representative of 3 experiments (**, P,0.005; ***, p,0.001).
doi:10.1371/journal.pone.0011311.g003
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PLoS ONE | www.plosone.org 7 June 2010 | Volume 5 | Issue 6 | e11311Figure 4. TRAMP-C2 cells partially activate iNKT cells by up-regulating activation markers and cell-contact dependently block
STAT4 phosphorylation in iNKT cells. A. TRAMP-C2 and BM-DC were pulsed with a-GalCer or vehicle and used as stimulators for liver MNC as
responder cells. Cell culture supernatants were measured 24 hrs (IL-4) and 48 hrs thereafter (IFNc) by ELISA. B. WT hepatic MNC were exposed
overnight to TRAMP-C2 cells, BM-DC, or left alone. Non-adherent cells were stained with indicated mAbs and analyzed by FACS. Histograms show
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specifically expressed higher levels of the early activation marker
CD69 as compared to iNKT cells in spleens of both groups and
conventional T cells in all groups (Fig. 5A).
It has been well documented that IL-12 is an adjuvant for the
IFNc production by iNKT cells [41,42]. The observed up-
regulation of the IL-12R led us to determine whether addition
of IL-12 induces IFNc production of iNKT cells in response to
TRAMP-C2 cells. Freshly isolated iNKT cells from healthy
mice were co-cultured in the presence of TRAMP-C2 cells or
BM-DC with addition of IL-12. Similar to results seen in
Fig. 4A, in the absence of a-GalCer, DC stimulated modest
production of IL-4, but not IFNc,f r o mi N K Tc e l l s( F i g .5 ,b a r
1). The addition of IL-12 enhanced IFNc production of iNKT
cells (Fig. 5B, bar 2), as previously described [42]. Furthermore,
aa -GalCer pulsed DC induced secretion of IL-2, IL-4, and
IFNc by iNKT cells.
Corroborating with the results shown in Fig. 4, TRAMP-C2
cells without addition of a-GalCer stimulated IL-4 production in
iNKT cells, but were not sufficient to induce IFNc responses
(Fig. 5A, bar 5). Furthermore, TRAMP-C2 cells did not induce IL-
2 responses by iNKT cells. Upon pulsing with a-GalCer,
TRAMP-C2 cells induced a significantly higher IL-2 and IL-4
production, but only minimal amounts of IFNc in iNKT cells
(Fig. 5B, bar 7).
When adding IL-12 to stimulations of iNKT cells by TRAMP-
C2 cells, we observed significant albeit minimal levels of IFNc
produced by iNKT cells (Fig. 5B, bar 6). The addition of IL-12 to
a-GalCer-pulsed TRAMP-C2 as stimulators was sufficient to
induce a significant production of IFNc in iNKT cells. These data
were corroborated by intracellular cytokine staining performed on
in vivo activated NK1.1
+ cells isolated from hosts of subcutaneous
TRAMP-C2 tumors. TRAMP-C2 cells were s.c. injected into WT
C57BL/6 mice. Two weeks after tumor seeding iNKT cells were
activated by i.p. injections of 1 mg a-GalCer with or without
500 ng IL-12. To inhibit cytokine export from cells, mice received
injections of Brefeldin-A five hours before liver MNC (Fig. 5C) and
spleen cells (data not shown) were isolated and stained for flow
cytometry. Injection of a-GalCer into untreated WT mice
stimulated iNKT cells to production of both IFNc and IL-4.
Comparable to in vitro stimulation data (Fig. 5B), iNKT cells from
liver and spleen of TRAMP-C2 injected animals produced IL-4
but not IFNc in response to a-GalCer (Fig. 5C; not shown). The
simultaneous injection of IL-12 and a-GalCer did restore the
ability to produce IFNc. Comparable data were obtained after
injecting tumor-bearing TRAMP mice with a-GalCer with and
without the addition of recombinant IL-12 showing a significant
increase of IFNc serum levels in response to a-GalCer and IL-12
compared to a-GalCer alone (Fig. 5D).
These data show that TRAMP-C2 cells stimulate iNKT cells to
produce IL-4 but not IFNc, which could not be stimulated by
addition of a-GalCer. The addition of both high-affinity CD1d
agonist a-GalCer and the adjuvant IL-12 were required to induce
IFNc production in iNKT cells in vitro and in vivo. IL-12
injection concomitant to a-GalCer stimulation reversed the
systemic iNKT defects TRAMP-C2 cells induced and restored
the activation of iNKT cells.
iNKT cells express both activating and inhibitory NK-like
receptors including Ly49 receptor types recognizing MHC class I
molecules. Subtypes C, I, and F of the Ly49 receptor contain
ITIM motif in the cytoplasmic domain and thereby suppress
positive signals exerted by cytokine and other receptors [43].
MHC class I staining of TRAMP-C2 cells revealed the expression
of MHC class I on the surface (Fig. 6, histogram) which is
supported with earlier of TRAMP-C2 cells as MHC class I low
expressing cells [44]. To address a conceivable negative effect of
inhibitory Ly49 receptors expressed on iNKT cells, Ly49
expression on iNKT cells was blocked. iNKT cells were then
stimulated with a-GalCer pulsed (or untreated) TRAMP-C2 cells
in the presence or absence of IL-12 and IFNc secretion measured
by ELISA. Confirming data shown in Fig. 5 both a-GalCer and
were required for IFNc production in iNKT cells stimulated by
TRAMP-C2. Blockade of Ly49 expression on iNKT cells during
cocultures with untreated TRAMP-C2 cells did not elicit any
detectable IFNc production (Fig. 6, bar graph). Blockade of
Ly49C/F/I/H receptors on liver MNC during co-incubation with
TRAMP-C2 cells in the presence of exogenous IL-12 restored
IFNc secretion to levels comparable those observed after co-
incubation with a-GalCer loaded TRAMP-C2 cells and IL-12.
To confirm a role of Ly49 receptors in vivo, we injected TRAMP
mice with Ly49 antibodies before iNKT cells were activated by a-
GalCer administration. Comparable to in vitro results (Fig. 6, upper
graph), Ly49 blockade significantly increased IFNc serum levels
elicited by a-GalCer administration. This suggests a role for NK-
like inhibitory receptors in iNKT cell defects. Comparable IFNc
levels were also induced by simultaneous injection of a-GalCer
and IL-12 (Fig. 5D).
Collectively, these data indicate that murine prostate tumor cells
induce a partial activation state in iNKT cells characterized by
STAT4 phosphorylation blockade. Although iNKT cells in this
state up-regulate the IL-12R, they are unable to respond to IL-12
in the absence of high affinity ligand. iNKT cell defects were
apparently at least partially mediated by MHC-I/Ly49 interaction
between prostate tumor and iNKT cells.
Discussion
Systemic numerical and functional iNKT cell defects have been
observed in cancer patients. iNKT cells of cancer patients showed
a significant reduction of IFNc in response to TCR-mediated
activation in vitro [5–9]. The mechanism(s) underlying the resulting
iNKT cell defects remain obscure. We sought to develop a suitable
mouse model to investigate such. In the TRAMP mouse prostate
tumor model, we found iNKT cells from cancer-bearing mice
exhibit functional defects similar to those observed in humans.
Specifically, upon activation with the CD1d ligand a-GalCer,
iNKT cells from tumor-bearing mice exhibited a diminished
production of both Th2 cytokines and IFNc. In addition, DCs
from these mice did not produce IL-12 upon interaction with
iNKT cells. These data are supported by a recent study of Bellone
et al. who reported a defective production of IFNc and IL-4 of
TRAMP mice in response to a-GalCer [5].
We characterized the interaction of iNKT cells from TRAMP
mice ex vivo compared to iNKT cells from healthy mice with the
expression of gated iNKT cells. C. Liver MNC were cultured overnight alone or in the presence of TRAMP-C2 cells, pretreated with saturating amounts
of anti-mouse CD1d blocking mAbs (3C11) or separated by 0.4 mm transwell membranes. Cells were then stimulated for 30 mins. with 10 ng/ml rIL-
12, immediately fixed and stained with mAbs against abTCR and NK1.1. Cells were then permeabilized using methanol and intracellularly stained
against phospho-STAT4 (Ser721). Histograms show phospho-STAT4 staining of electronically gated NKT cells (abTCR
+NK1.1
+) shown in left plot. Data
shown are representative results of two experiments.
doi:10.1371/journal.pone.0011311.g004
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Figure 5. IL-12 combined with a-GalCer restores the ability to activate iNKT cells in response to prostate tumor cells. A. IL12Rb1
expression on TIL-iNKT and T cells from primary TRAMP prostate tumors, TRAMP spleen and WT spleen ex vivo. Contour plot shows presence of iNKT
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CaP lines and primary TRAMP tumors expressed CD1d.
TRAMP-C2 cells activated iNKT cells from healthy mice in a
CD1d-dependent fashion to produce IL-4, but not IFNc. These
findings prompted us to hypothesize that these tumor cells may
aberrantly activate iNKT cells. TRAMP-C2 cells induced the
expression of the activation markers CD25, PD-1 and IL-12Rb1
on iNKT cells. It should be stressed that TRAMP-C2 tumor cells
activated iNKT cells without addition of the exogenous ligand a-
GalCer. This is corroborated by our findings that TRAMP-C2
cells induced the secretion of IL-4, but not IFNc. Production of IL-
4 has been shown to occur independently of co-stimulatory
molecules presented by CD1d
+ DC, whereas the production of
IFNc is enhanced by IL-12 produced by DC [15]. Importantly,
while iNKT cells up-regulated the IL-12R in response to
TRAMP-C2 cells, the addition of IL-12 alone was not sufficient
to stimulate their IFNc production. Additionally, TRAMP-C2
cells blocked STAT4 signaling downstream of the IL-12 receptor.
Phosphorylation in residues Ser721 and Tyr693 is critical for
transactivation of STAT4 [40]. This inhibition was cell-cell
contact dependent. The lack of effect of saturating amounts of
blocking CD1d antibody strongly suggests IL-12R inhibition is
independent of CD1d expression on TRAMP-C2 cells. This is
corroborated by the inhibitory effect of Ly49 on NKT cells during
culture with a-GalCer loaded TRAMP-C2 cells and in tumor-
bearing TRAMP mice in vivo.
The functional inhibition of IFNc production was reversible by
the simultaneous addition of both IL-12 and the high-affinity
ligand a-GalCer, thus showing that tumor cells reversibly inhibit
iNKT cells. This inhibition can be overcome by addition of strong
TCR signals, such as provided by the high affinity ligand a-
GalCer (Fig. 6). Our further results suggest inhibitory Ly49
receptors play a role in the observed iNKT cells defects. TRAMP-
C2 cells express MHC class I molecules at low levels, thus
providing a potential explanation for our findings that Ly49
blockade alone does not completely rescue the IFNc production,
but still requires the presence of a-GalCer as a high-affinity ligand
for CD1d. In the absence of a-GalCer TRAMP-C2 were able to
stimulate the production of IL-2 in DN32 and IL-4 in iNKT cells.
Further studies will be needed to elucidate the identity of the
CD1d ligand expressed by TRAMP-C2 cells.
Additionally, we show that subcutaneously injected TRAMP-
C2 cells inhibit iNKT cells systemically to i.p. injection of a-
GalCer, which was reversible by simultaneous administration of a-
GalCer and IL-12. Similar effects were obtained by blockade of
inhibitory Ly49 receptors in TRAMP mice. Since free injected a-
GalCer injected in vivo binds DCs and other APC, we conclude
that TRAMP-C2 tumors systemically inhibit the response of
experiments. B. Liver MNC were cultured in the presence or absence of IL-12 with TRAMP-C2 or DC pulsed with a-GalCer or vehicle for 24 or 48 hrs.
Cell culture supernatants were tested for cytokine secretion by ELISA. Data shown are representative of 3 experiments (*, P,0.05; ***, p,0.001; n.s.,
not significant). C. WT C57BL/6 mice were injected with TRAMP-C2 cells s.c. or left untreated. Two weeks thereafter, mice were injected with 150 mg
Brefeldin-A and 1 mg a-GalCer with or without IL-12. Five hours later, spleen cells were stained with mAbs against abTCR and NK1.1, followed by
permeablization and subsequent intracellular staining with mAbs against IL-4, IFNc, or rat IgG isotype controls. Histograms show total cytokine
expression of gated NK1.1
+ cells. D. Tumor-bearing TRAMP mice were i.p. injected with a-GalCer with or without recombinant IL-12. IFNc levels from
sera taken 90 mins later were determined by ELISA (n=3, *, p,0.05).
doi:10.1371/journal.pone.0011311.g005
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lack of cell-contact between subcutaneous TRAMP-C2 and
splenic iNKT cells suggests this inhibition is mediated by soluble
factors. Systemic APC defects in iNKT cell presentation in cancer
patients and rodent tumor models have been reported [45].
We conclude from these findings that tumor cells directly block
the production of IFNc cytokines in iNKT cells. iNKT cells may
store cytokine mRNA, allowing them to respond rapidly upon
TCR-mediated activation [46]. Thus, it is conceivable that prostate
tumor cells, in addition to CD1d-mediated signals activating iNKT
cells deliver additional signals that block the translation or export of
IFNc in iNKT (Fig. 7). Whether the IFNc blockade is mediated by
tumor-derived soluble factors is currently not known.
These in vitro findings are further corroborated by our ex vivo
data showing the expression IL-12Rb1 and CD69 on iNKT cells
in TRAMP prostate tumors. Despite the high expression of CD69,
TIL-iNKT cells did not express CD25, which upon activation is
expressed at later timepoints compared to CD69. Whether this is
due to a higher turnover of TIL-iNKT cells in the tumor by
apoptosis, remains to be clarified. Future experiments will be
needed to investigate whether the aberrant activation of iNKT
cells seen in murine prostate tumors can be observed in advanced
prostate cancer patients Notably, like human prostate tumors and
CaP cell lines [25,26], TRAMP prostate tumor cells secrete high
amounts of the chemokine CCL2 and attracted iNKT cells into
the TME without detectable depletion of iNKT cells elsewhere.
This argues for a higher turn-over rate. Specifically, only iNKT
cells in the prostate tumors but not spleens of tumor-bearing mice
(or control mice) showed an activated phenotype. This suggests
that the local presence of tumor cells is required for this effect.
In conclusion, by using the T-antigen induced prostate cancer
TRAMP mouse, whose disease resembled features of human PCa
disease, we developed a suitable model to study iNKT cell defects
and their reversion. We show that prostate tumor cells, induce a
novel and partial activation state in iNKT cells. Concomitantly,
prostate tumor cells directly inhibit secretion of IFNc as a effector
function in iNKT cells. This effect was resistant to IL-12. The
correction of these iNKT cell defects by CD1d ligand a-GalCer
with IL-12 might support future development of IL-12R and
iNKT-targeted therapeutic approaches.
Supporting Information
Figure S1 PD-L1 blockade does not restore TRAMP-C2
mediated IFNc secretion in iNKT cells. TRAMP-C2 cells were
loaded with a-GalCer vigorously washed and incubated with anti-
PDL1 mAbs or isotype controls before freshly isolated liver MNC
prestained with mAbs against abTCr and NK1.1 were added as
responder cells. Cocultures were carried out in the presence of
Brefeldin A for 6 hours before intracellular IFNc staining was
performed. Data shown are of iNKT cells gated as
abTCR+NK1.1+ cells. Results shown are representative of two
experiments. Bottom right histogram: TRAMP-C2 cells do not
express PD-L1. TRAMP-C2 cells (bold line) or BM-DC (dashed
line) were stained with anti-PD-L1 TRAMP-C2or rat IgG2b
isotype control mAbs (dotted line), followed by anti-rat IgG FITC
mAbs and analyzed by FACS.
Found at: doi:10.1371/journal.pone.0011311.s001 (1.32 MB EPS)
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